Showing 5601-5610 of 8729 results for "".
- Bio-Oil Celebrates Body Confidence Through Body Positivity Month Campaignhttps://practicaldermatology.com/news/bio-oil-celebrates-body-confidence-through-body-positivity-month-campaign/2461538/Bio-Oil is rolling out a month-long campaign in celebration of February's Body Positivity Month to encourage self-love, promote body confidence, and highlight the role that Bio-Oil plays in helping people to love their stretch marks due to pregnancy, to scars from surgical procedur
- Mount Sinai Physician Promises $5 Million Bequest to Support the Kimberly and Eric J. Waldman Department of Dermatologyhttps://practicaldermatology.com/news/mount-sinai-physician-promises-5-million-bequest-to-support-the-kimberly-and-eric-j-waldman-department-of-dermatology/2461536/The Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai received a $5 million bequest promised by Kenneth L. Edelson, MD, Clinical Professor of Dermatology. This gift represents Dr. Edelson’s commitment to advancing dermatolo
- Sirnaomics Accelerates Clinical Development of STP705 for isSCC, BCChttps://practicaldermatology.com/news/sirnaomics-accelerates-clinical-development-of-stp705-for-isscc-bcc/2461535/Sirnaomics Ltd. is advancing the clinical development of STP705 for the treatment of squamous cell carcinoma in situ (isSCC) and basal cell carcinoma (BCC). Based on positive clinical readouts from a Phase IIb study for isSCC and a Phase II study for BCC, Sirnaomics is formul
- Game On: Top Derm Video Game Boosts Clinical Decision Making Among Seasoned Doctorshttps://practicaldermatology.com/news/game-on-top-derm-video-game-boosts-clinical-decision-making-among-seasoned-doctors/2461534/Medical video games increase the competence and clinical decision-making of practicing physicians, a new study by Level Ex shows. Substantial research has demonstrated video-game-based medical training’s effectiveness in the short-term. These studies primarily focused on medi
- Spotlight on: Lanolin Allergenicityhttps://practicaldermatology.com/news/spotlight-on-lanolin-allergenicity/2461531/The phenomenon of lanolin allergenicity is the focus of the Contact Allergen of the Year article in <
- CDC Report: Seven Percent of Adults and 11 Percent of Kids Had Eczema in 2021https://practicaldermatology.com/news/cdc-report-seven-percent-of-adults-and-11-percent-of-kids-had-eczema-in-2021/2461530/Slightly more than 7% of adults and nearly 11% of kids had eczema in 2021, according to two new reports in the CDC’s National Center for Health Statistics Data Brief. W
- Phase 2 Data: Jeuveau “Extra-Strength” Dose Produces Lasting Resultshttps://practicaldermatology.com/news/phase-2-data-jeuveau-extra-strength-dose-produces-lasting-results/2461528/Evolus' Jeuveau Extra-Strength achieved one-point improvement on the Glabellar Lines Scale with the duration of effect lasting 26 weeks, representing a prolonged 6-month performance, the Company reports. The extra-strength glabellar line study is a multicenter, double
- Study: 3D-printed Artificial Skin Can Be Used in Cosmetics and Drug Testinghttps://practicaldermatology.com/news/study-3d-printed-artificial-skin-can-be-used-in-cosmetics-and-drug-testing/2461525/Bioprinted artificial skin can be used in cosmetics and drug testing, a new study shows. For the study, researchers compared the conventional mimetic model based on manual pipetting with extrusion bioprinting, which “allows the in vitro reconstruction of a more relevant and repres
- Meet FACE by Galdermahttps://practicaldermatology.com/news/meet-face-by-galderma/2461524/Galderma is launching FACE by Galderma, an app that simulates the results of injectable treatments in real time using digital facial assessment. The technology was unveiled at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris. FACE by Galder
- Bristol Myers Squibb Receives Positive CHMP Opinion for Once-Daily Sotyktu as Plaque Psoriasis Treatmenthttps://practicaldermatology.com/news/bristol-myers-squibb-receives-positive-chmp-opinion-for-once-daily-sotyktu-as-plaque-psoriasis-treatment/2461522/Four months after receiving FDA approval, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended the approval of Sotyktu (deucravacitinib; Bristol Myers Squibb) for the treatment of adults with moderate-to-severe plaque psoriasis.